The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape
Watch leading experts from Pfizer, Merck, Amicus, and Certara discuss how Integrated Evidence can bridge…
Certara2025 年 9 月 3 日
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)
Learn to design drug development programs for First-in-Human (FIH) success with biomarkers, PK/PD modeling, and…
Certara2025 年 8 月 29 日
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value
Discover strategies to cut risk, speed timelines, and boost investor confidence in early biotech development.
Certara2025 年 8 月 21 日
ToxStudio®: In silico tools to accelerate toxicology assessments
Watch to explore ToxStudio—in silico toxicology platform designed to address key preclinical safety challenges.
Certara2025 年 8 月 19 日
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
Certara2025 年 8 月 13 日
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
Certara2025 年 8 月 13 日
Replacing traditional TQT studies with model-based concentration-qtc (C-qtc) analysis for cardiovascular safety in drug development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
Certara2025 年 8 月 6 日
Breaking new ground: EMA qualification of the Simcyp® Simulator ushers in a new era for PBPK modeling
The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…
Certara2025 年 8 月 5 日
